Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Insulin Resistance 5 Hyperglycemia 3 Polycystic Ovary Syndrome 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Oligomenorrhea 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Intracranial Aneurysm 1 Hypoglycemia 1 Hyperphagia 1 Hyperinsulinism 1 Hyperandrogenism 1 Hirsutism 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus, Type 1 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 185 Gemcitabine 170 Paclitaxel 152 Carboplatin 137 Bevacizumab 128 Surveys and Questionnaires 118 Cisplatin 115 Docetaxel 114 Blood Specimen Collection 110 Cyclophosphamide 109 Exercise 108 Nivolumab 99 Fluorouracil 90 Capecitabine 86 Radiotherapy 81 Dexamethasone 81 Irinotecan 74 Standard of Care 69 Pemetrexed 68 Oxaliplatin 68 Drug Therapy 65 Leucovorin 64 Cetuximab 60 Erlotinib Hydrochloride 56 atezolizumab 53 Sorafenib 53 Ipilimumab 51 Doxorubicin 50 trametinib 47 Interviews as Topic 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Insulin × Clear all

NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡